Startups Swimming i...
Health Care: Drugs
Isis Pharmaceuticals (ISIS: NASDAQ)
$20.64 0.25 | 1.23%
05/23/13 - 04:00 PM ET
Company Profile
| Price and Volume | |
|---|---|
| Recent Price | 20.64 |
| 52 Week High | 23.03 |
| 52 Week Low | 7.56 |
| Avg. Daily Vol. (Mil) | 1.63 |
| Beta (3 year) | 1.69 |
| Share Related Items | |
| Mkt Cap (Mil) | 2,142.03 |
| Shares Out (Mil) | 103.78 |
| Float (Mil) | 85.89 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 5.90 |
| Current Ratio | 6.10 |
| LT Debt/ Equity | 1.11 |
| Total Debt / Equity | 1.13 |
| Valuation Ratios | |
| Price Earnings | n.a. |
| Price/Sales | 17.53 |
| Price/Book | 10.65 |
| Price/Cash Flow | -169.00 |
| Per Share Data | |
| Earnings | -0.42 |
| Sales | 1.18 |
| Book Value | 1.94 |
| Cash Flow | -0.12 |
| Business Summary | |
|---|---|
| Isis Pharmaceuticals is engaged in antisense drug discovery and development, exploiting a novel drug discovery platform it created to generate a broad pipeline of first-in-class drugs. | |
| General Information | |
| 2855 Gazelle Court
Carlsbad, CA 92010 |
|
| www.isispharm.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 342 | |
| CEO: Dr. Stanley T. Crooke,M. | |
| Short Interest | |
| Current Month (Mil) | 13.02 |
| Previous Month (Mil) | 13.82 |
| Short Interest Ratio (Days) | 9.00 |
| Management Effectiveness | |
| Return on Equity | n.a. |
| Return on Assets | -7.80 |
| Return on Investments | -10.00 |
| Profitability | |
| Gross Margin | n.a. |
| EBIT Margin | -50.80 |
| Profit Margin | -35.30 |
Portfolios with ISIS
- Portfolio NameUser Type
- ContributorStocks Rising On Unusual Vo...
- ContributorBreakout Stocks Of The Week...
- ContributorStocks Rising On Unusual Vo...
- UserCy Winther
- ContributorDrugs Facing FDA Approval i...
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks Under-$10 Setting Up...
- ContributorUnder-$10 Setting Up To Tra...
- UserNext Generation
- Contributor10 Biotech Stocks on Clinic...
Latest ISIS Headlines from TheStreet
- Isis Stock Falls On Unusually High Volume (ISIS) 05.08.13 | 04:05 pm
- Isis Reaches New 52-Week High (ISIS) 05.03.13 | 10:05 am
- Cramer's 'Mad Money' Recap: Good Earnings, Bad Market 05.01.13 | 08:05 pm
- Isis Stock Hits New 52-Week High (ISIS) 04.19.13 | 09:04 am
- Cramer's 'Mad Money' Recap: Risk vs. Reward 04.03.13 | 08:04 pm
- Biotech Stock Mailbag: Celsion, Navidea, AP Pharma, Sarepta 02.01.13 | 07:02 am
- 4 Stocks Rising on Big Volume 01.31.13 | 08:01 am
- Aegerion CEO Speaks On Juxtapid Launch, Orphan Drug Pricing And Competition 01.30.13 | 06:01 am
- Isis Pharmaceuticals Stock Upgraded (ISIS) 01.28.13 | 04:01 am
- 'Mad Money' Lightning Round: I'd Buy Duke Energy 01.24.13 | 06:01 am
Press Releases for ISIS
- Isis Pharmaceuticals To Present At The Deutsche Bank 38th Annual DbAccess Health Care Conference - PR Newswire 05.23.13 | 07:05 am
- Isis Pharmaceuticals To Present At The 2013 UBS Global Healthcare Conference - PR Newswire 05.13.13 | 07:05 am
- Isis Pharmaceuticals Earns $3.5 Million From Biogen Idec - PR Newswire 05.09.13 | 04:05 pm
- Isis Pharmaceuticals To Present At The Bank Of America Merrill Lynch 2013 Health Care Conference - PR Newswire 05.09.13 | 02:05 pm
- Isis Pharmaceuticals Prices Public Offering Of Common Stock - PR Newswire 05.08.13 | 09:05 pm
- Isis Pharmaceuticals Announces Proposed Public Offering Of Common Stock - PR Newswire 05.07.13 | 04:05 pm
- Isis Pharmaceuticals Announces The Initiation Of A Clinical Study Of ISIS-STAT3 Rx In Patients With Liver Cancer - PR Newswire 05.06.13 | 07:05 am
- ISIS Pharmaceuticals Initiates A Clinical Study Of ISIS-SMN Rx In Infants With Spinal Muscular Atrophy - PR Newswire 04.23.13 | 07:04 am
- Isis Pharmaceuticals To Present At The 12th Annual Needham Healthcare Conference - PR Newswire 04.22.13 | 05:04 pm
- Roche And Isis Pharmaceuticals Form Alliance For Huntington's Disease - PR Newswire 04.08.13 | 09:04 am
Partner Headlines for ISIS
- Cree, Seagate, Sandisk: Why Richie Freeman Likes Them - Investor's Business Daily 04.02.13 | 06:04 pm
- Isis Pharma Issues Update on CHMP Opinion on KYNAMRO - Benzinga 03.22.13 | 02:03 pm
- Revenues Decline at Alnylam - Analyst Blog - Zacks 11.07.12 | 09:11 am
- Isis Pharmaceuticals To Receive $1.1 Million From Alnylam - Benzinga 10.23.12 | 01:10 pm
- Benzinga Mid-Day Market Update - Benzinga 10.17.12 | 12:10 pm
- UPDATE: Piper Jaffray Downgrades ISIS Pharmaceuticals to Neutral on FDA Briefing - Benzinga 10.16.12 | 01:10 pm
- Alnylam-ISIS Venture Prices IPO - Analyst Blog - Zacks 10.05.12 | 06:10 pm
- Alnylam/Isis's Regulus to Go Public - Analyst Blog - Zacks 08.22.12 | 07:08 pm
- Biogen Inks Deal with Regulus - Analyst Blog - Zacks 08.16.12 | 06:08 pm
- Pre-Market Most Active for Aug 8, 2012 : WFR, QQQ, NOK, BAC, TEF, DF, KCG, SODA, ISIS, SIRI, FB, ASML - NASDAQ 08.08.12 | 12:08 pm
